5George J M,Towne T G,Rodvold K A. Prolonged infusions of β- lactam antibiotics: implication for antimicrobiai stewardship[J].Pharmacotherapy, 2012,32 (8) : 707-721.
4Rhomberg P R, Jones R N. Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: Report from the MYSTIC Program (2002) in North America[J]. Diagn Microbiol Infect Dis, 2003, 47( 1 ): 365 -372.
5Conte J E, Golden J A, Kelley M G, et al. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem[J]. Int J Antimicrob Agents, 2005, 26(6): 449 -456.
6Abo EI-Sooud K. Plasma pharmacokinetics and urine concentrations of meropenem in ewes[J] . J Vet Pharmacol Ther, 2004, 27 ( 1 ) : 27 - 30.
7Fish D N, Singletary T J. Meropenem, a new carbapenem antibiotic[J]. Pharmacotherapy, 1997, 17(4): 644 - 669.
8Turnidge J D. The pharmacodynamics of beta-lactams[J]. Clin Infect Dis, 1998, 27(1): 10~22.
9Drusano G L. Prevention of resistance: A goal for dose selection of antimlcrobial agents[J]. Clin Infect Dis, 2003, 36 (Suppl 1 ): s42 - s50.
10Bustamente C I, Drusano G L, Tatem B A, et al. Postantibiotic effect of imipenem on Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 1984, 26 (5) : 678 - 682.
